New treatment approach for tuberculosis and HIV using targeted immunotherapy
Targeted cell-depleting immunotherapy for TB and HIV
This study is testing a new treatment that helps boost the immune system to fight tuberculosis and HIV by targeting certain cells that weaken the immune response, and it's designed for patients looking for better ways to manage these infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10763827 on NIH RePORTER |
What this research studies
This research investigates a novel immunotherapy that targets specific immune cells involved in tuberculosis (TB) and HIV infections. The approach utilizes biologic agents designed to selectively deplete regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which are known to suppress the immune response against these infections. By using diphtheria toxin fusion proteins, the study aims to enhance the immune system's ability to fight TB and reactivate HIV in controlled patients, potentially leading to more effective treatments. Patients may benefit from improved therapies that better manage or eliminate these infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis or HIV, particularly those with controlled HIV who may benefit from reactivation therapies.
Not a fit: Patients with active, uncontrolled HIV or those who do not have tuberculosis may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from tuberculosis and HIV.
How similar studies have performed: Previous research has shown promise in targeting immune suppressor cells for enhancing immune responses, indicating potential success for this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Bishai, William Ramses — Johns Hopkins University
- Study coordinator: Bishai, William Ramses
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.